Maplight Therapeutics (NASDAQ:MPLT) CFO Sells $418,951.44 in Stock

Key Points

• Maplight CFO Vishwas Setia sold a total of 36,371 shares across May 4–6 under a pre‑arranged Rule 10b5‑1 plan for roughly $1.02 million, leaving him with 377,723 shares (~$10.6M), a 3.8% reduction in his position.
• The company reported a Q1 EPS miss (‑$2.47 vs. consensus ‑$1.05) and trades with a negative P/E, with analysts forecasting FY EPS around ‑3.96, highlighting continued losses and cash‑burn risk.
• Analyst sentiment is mixed but leans positive: MarketBeat shows a consensus rating of Moderate Buy and a $34.43 target, while several firms (including HC Wainwright and Needham) have issued Buy ratings and higher price targets.

Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) CFO Vishwas Setia sold 14,904 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $28.11, for a total transaction of $418,951.44. Following the transaction, the chief financial officer directly owned 377,723 shares in the company, valued at approximately $10,617,793.53. This represents a 3.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vishwas Setia also recently made the following trade(s):

• On Wednesday, May 6th, Vishwas Setia sold 10,564 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.24, for a total value of $298,327.36.
• On Tuesday, May 5th, Vishwas Setia sold 10,903 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.20, for a total value of $307,464.60.

Maplight Therapeutics Stock Performance

Maplight Therapeutics stock traded up $1.12 during midday trading on Wednesday, hitting $29.04. 267,979 shares of the stock were exchanged, compared to its average volume of 342,018. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $33.28. The stock has a market cap of $1.24 billion and a price-to-earnings ratio of -0.73. The company has a 50 day simple moving average of $22.60.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last released its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($1.42). On average, equities research analysts anticipate that Maplight Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Institutional Trading of Maplight Therapeutics

Large investors have recently added to or reduced their stakes in the business. Strs Ohio bought a new stake in Maplight Therapeutics in the fourth quarter worth approximately $53,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Maplight Therapeutics during the 4th quarter valued at $70,000. New York State Common Retirement Fund acquired a new position in Maplight Therapeutics during the 4th quarter valued at $93,000. MetLife Investment Management LLC acquired a new position in Maplight Therapeutics during the 4th quarter valued at $172,000. Finally, Walleye Capital LLC acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at $205,000.

Analyst Ratings Changes

A number of brokerages recently weighed in on MPLT. Wall Street Zen downgraded shares of Maplight Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They issued a "buy" rating and a $35.00 price target for the company. TD Cowen started coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They issued a "buy" rating for the company. HC Wainwright started coverage on shares of Maplight Therapeutics in a report on Monday. They issued a "buy" rating and a $45.00 target price on the stock. Finally, Needham & Company LLC began coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a "buy" rating and a $37.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $34.43.

Trending Headlines about Maplight Therapeutics

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its "Buy" rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a "Buy" rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright's detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.